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Abstract
Management of coagulopathy is a crucial aspect of care for hospitalized burn 
patients, especially intraoperatively during burn surgery. It is estimated that 
approximately one-third of blood products utilized during an average burn injury 
hospitalization are administered intraoperatively during excision of the primary 
wound and donor sites. Moreover, transfusion of blood products alone during burn 
surgery does not constitute an adequate method to achieve hemostasis. Biosurgical 
hemostats should be utilized as adjunctive therapeutic agents to minimize blood 
loss. Potential options include topical or tumescent epinephrine, fibrin sealants, 
calcium alginate, platelet rich plasma, topical or intravenous tranexamic acid, 
NuStat®, recombinant tissue factor, hydrogen peroxide, and oxidized regenerated 
cellulose. The most abundant clinical evidence is available for the use of topical 
and tumescent epinephrine and fibrin sealants to achieve hemostasis during burn 
surgery. The epinephrine technique has been shown to be generally safe, without 
clinically significant cardiovascular effects from systemic absorption. For fibrin 
sealants (FS), it is important that surgeons recognize that not all FS are the same, 
and that different formulations or products may behave in a slightly different 
fashion. For the other available hemostatic available hemostatic options, further 
research is needed to fully elucidate their potential roles and utility in minimizing 
blood loss during burn surgery.
Keywords: biosurgical hemostats, fibrin, hemorrhage control, surgical bleeding, 
thrombin
1. Introduction
Management of blood loss throughout a burn patient’s hospital course is a 
critical part of global care of those with thermal injuries. Patients suffering major 
(20–59% Total Body Surface Area (TBSA)) or massive (>60% TBSA) burns experi-
ence coagulopathic complications similar to those reported in major trauma or 
septic shock [1, 2] – a reflection of the systemic impact of such massive injury 
burden. Burn-related endothelial injury causes the release of tissue factor from a 
proportionately large surface area, contributing to the generation and consump-
tion of thrombin, fibrin, and other coagulations factors [3–7]. Platelet activation 
and consumption leads to thrombocytopenia that nadirs between 3 and 5 days 




Application method(s) Utility in burn surgery
Epinephrine Topical or tumescent; a 
typical solution is prepared as 
1:1,000,000 epinephrine in 
normal saline, which constitutes 
a dilution of 1 mL of 1:1,000 
epinephrine into 1 L of normal 
saline; lidocaine may be added
Long utilized in burn surgery for obtaining 
hemostasis, decreasing intraoperative blood 
loss, and substantially reducing rates of blood 
transfusions; generally safe, without clinically 




A fine spray to create a thin 
layer resulting in approximately 
0.05–0.06 mL/cm2 material 
distribution
Benefits include effective graft fixation, decreased 
hematoma and seroma formation, and shorter 
operative times; graft-take may be enhanced by 
the fibrin clot scaffold even when wound bed 
is infected; can also be used on the donor site to 
improve the time to hemostasis; excellent safety 
profile; important that surgeons recognize that 
not all FS are the same - different formulations or 
products may behave in a slightly different way
Calcium 
alginate
Donor-site dressing In comparison to epinephrine and fibrin-based 
products, not as effective as hemostatic agent; as 
donor-site dressing, has been observed to provide 
superior hemostasis for skin-graft donor sites 
when compared to plain sterile gauze or paraffin 
gauze dressings; risk of dermal calcifications
Platelet rich 
plasma (PRP)
Topical application Studies on use in burn surgery are scarce; while 
platelets in burn patients appear to have normal 
functionality, further studies focusing on the 
quantitative hemostatic ability of PRP in the 
setting of thermal injury are needed
Figure 1. 
Schematic presentation of pathophysiologic mechanisms affecting coagulation in patients who sustained severe 
burn injuries. Legend: SIRS = systemic inflammatory response syndrome. Schematic adopted from Glas, et al. 
2016.
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after injury [8]. In addition, there are important secondary factors that contribute 
to coagulopathy including hemodilution from resuscitation, hypothermia, and 
acidosis (Figure 1) [1, 9, 10].
In general, greater burn size correlates with increased duration of surgery, num-
ber of required operative procedures, and need for blood transfusion [11, 12]. For 
every 1% of total body surface excised, including surface area of skin graft donor 
site, a patient can experience as much as 10% loss of their calculated blood volume 
[13]. Since intraoperative blood loss from both excision of primary wound and 
donor sites can account for about one-third of blood products administered dur-
ing an average burn injury hospitalization, minimizing blood loss in the operating 
room (OR) is vital for minimizing overall transfusion requirements [14, 15]. Blood 
product resuscitation alone is not sufficient for hemostasis and carries significant 
associated risks, which opens up an important opportunity for the consideration of 
topical hemostatic adjuncts in the overall blood management of the burned patient 
[8, 16, 17]. This chapter focuses on the roles of biosurgical hemostats as they pertain 
to the transfusion reduction strategy in the setting of thermal injury (Table 1).
2. Overview of biosurgical hemostats in burn surgery
There are different types of available biosurgical hemostats, as outlined in 
Table 1. For the purposes of the current chapter, it is important to recognize that 
a gap exists between provider awareness of this class of adjunctive hemostatic 
agents and their actual clinical application. Arguably, the latter is much more 
extensive than one might initially realize or admit. It is therefore important to bring 
Biosurgical 
hemostat
Application method(s) Utility in burn surgery
Tranexamic 
acid (TXA)
Administered topically or 
intravenously
Few studies exist evaluating the use of TXA in 
burn patients; however, overall available data is 
promising; one study demonstrated no difference 
in mortality or thromboembolic disease, and 
some improvement of graft survival in the TXA 
group
NuStat® Topical dressing While one RCT showed clinical equivalency 
of NuStat® compared to historic standard 
of care, the overall cost of wound care was 




Topical application 2017 phase II randomized parallel double-blinded 




Topical (3% soak applied to the 
tangential excision site)
Investigators reported no complications related 
to corrosive damage or lipid peroxidation; needs 
to be sufficiently irrigated from the wound bed 





Topical application Limited literature exists on the use of ORC in 
burn surgery
Abbreviations: RCT = randomized controlled trial.
Table 1. 
Summary of biosurgical hemostats in burn surgery.
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biosurgical hemostats into focus as increasing emphasis is being placed on reduction 
in unnecessary blood/blood product transfusions across burn centers and critical 
care units.
3. Epinephrine
Epinephrine has long been used in burn surgery for obtaining hemostasis at both 
the wound excision site and donor site, decreasing intraoperative blood loss per 
area excised, and substantially reducing rates of blood transfusions (in some cases 
by as much as 50%) [18, 19]. When applying epinephrine to any operative site, a 
pre-made solution can be applied topically or injected as a tumescent solution [20]. 
Although exact concentrations and application modality may vary between institu-
tions, a typical solution is prepared as 1:1,000,000 epinephrine in normal saline, 
which constitutes a dilution of 1 mL of 1:1,000 epinephrine into 1 L of normal 
saline [21, 22]. Addition of lidocaine to the above solution has also been described 
to help decrease postoperative pain, duration of surgery, general anesthesia, and 
potentially accelerate re-epithelialization of the donor site [23].
The tumescent technique significantly decreases intraoperative blood loss and 
has been shown to be generally safe, without clinically significant cardiovascular 
effects due to systemic absorption [19, 24, 25]. Typically, the diluted epinephrine 
is injected subcutaneously with either a long 18-gauge spinal needle or a blunt 
liposuction cannula with injector. When properly performed, the subcutaneous 
injection under the desired area causes the area to become firm (tumescent) and the 
overlying skin to blanch. Whether used at the donor site or the eschar excision site, 
the firm vasoconstricted surfaces tend to be better prepared for subsequent excision 
[18], both in terms of technical ease of the operation and decreased blood loss.
The same diluted epinephrine solution can also be used as a topical hemostatic 
agent at both the donor and wound excision sites. This is most commonly per-
formed by soaking non-adherent gauze, such as specially coated cotton pads, in 
the epinephrine solution and then applying the pads directly to the freshly excised 
area. It should be noted that this is performed as a hemostatic maneuver only after 
any major or brisk surgical bleeding has first been controlled. The epinephrine 
solution soaked non-adherent gauze can be secured in place by lightly wrapping it 
with a bandage roll. Typically, these are allowed to stay in place for 10–20 minutes 
to allow for hemostasis to occur. Careful removal is important for preventing 
disruption of the newly formed clot. If any residual oozing is present, new gauze 
can be re-applied until adequate hemostasis is achieved. In the absence of non-
adherent gauze, the epinephrine solution can alternatively be applied topically as 
a spray or gelatinous mixture (e.g., using water-based lubricant as an application 
medium) [26, 27]. Other vasoactive hemostatic agents utilized in burn surgery 
include terlipressin and phenylephrine, with associated literature descriptions of 
reportedly positive effects in terms of blood loss reduction and other operative 
characteristics [22, 28–32].
4. Fibrin sealants
Fibrin is the hemostatic product of thrombin-mediated cleavage of fibrinogen 
[33]. Understanding the relationship between fibrinogen and thrombin has allowed 
for pharmaceutical companies to develop a variety of fibrin-based products, includ-
ing those designed for hemostatic applications [34, 35]. Although fibrin sealants 
(FS) have been used since 1909, with reported use on skin grafts as early as 1944, 
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the first formal U.S. Food and Drug Administration (FDA) approval of a FS for use 
with skin grafts – including those performed in burn surgery – did not come until 
2008 (Artiss®, Baxter, Westlake Village, CA) [36]. Other similar products that fall 
within the class of “fibrin sealants” have been effectively used in the setting of skin 
grafts, with similar results [37–39].
Surgeons must recognize that not all FS are the same, and that different 
 formulations or products may not always produce identical results. There are 
important differences across available products that one must understand in order 
to optimize clinical outcomes for the burn patient. The products available provide 
a range of concentration ratios of fibrinogen and thrombin solutions, which are 
combined and “mixed” during application. For example, Artiss® (Baxter, Westlake 
Village, CA) contains a ratio of 67–106 mg/mL fibrinogen to 2.5–6.5 units/mL 
thrombin [40], whereas Tisseel® (Baxter; Deerfield, IL, US) contains a ratio of 
67–106 mg/mL fibrinogen to 400–625 units/mL thrombin [41]. Although both 
products contain similar amount of fibrinogen, the latter has 100-fold more throm-
bin. Higher concentrations of thrombin will speed up the polymerization process, 
decreasing clotting and sealing time. With regards to the aforementioned products, 
increasing the thrombin concentration by 100-fold effectively shortens the polym-
erization time from minutes to seconds. This difference is so robust that Tisseel® is 
FDA approved as a hemostatic agent, while Artiss® is not. When hemostasis is less 
of a concern and the intended use is primarily for sealant/fixation purposes, having 
a slower polymerization time is better suited for manipulating a skin graft into the 
desired location and orientation. Similar therapeutic outcomes have been reported 
using a variety of component concentrations, within a pre-specified range [42].
Benefits of using FS in burn surgery include effective graft fixation, decreased 
hematoma and seroma formation, and shorter operative times [42–44]. There may 
also be an added benefit in terms of improved postoperative pain, especially when 
compared to alternative skin graft fixation modalities such as staples or sutures 
[36, 45]. When applied correctly, ideally as a fine spray to create a thin layer that is 
only about 0.05–0.06 mL/cm2 thick, the graft-take may be enhanced by the fibrin 
clot scaffold which promotes migration of fibroblasts, epithelial cells, and keratino-
cytes [42, 46]. Even when the wound bed is infected, FS use may improve graft take 
by reinforcing graft adherence to the wound bed [47]. FS can also be used on the 
donor site to improve the time to hemostasis [48].
Taken collectively, FS have an excellent overall safety profile [44, 49, 50]. 
Historically, complications from exposure to bovine-derived thrombin have been 
reported, including the subsequent development of anti-bovine thrombin antibod-
ies. Associated morbidity included bleeding, thromboembolisms, hypersensitivity 
reactions, and prolonged activated partial thromboplastin times (aPTT) [51]. 
However, most currently available FS are made with recombinant thrombin, which 
is far less immunogenic [52]. In fact, a meta-analysis of 10 clinical trials showed 
that at 1 month from surgery, less than 1% of patients exposed to recombinant 
thrombin will develop antibodies against it [53]. Furthermore, unlike anti-bovine 
thrombin antibodies, anti-recombinant thrombin antibodies do not neutralize 
activity of native human thrombin [53, 54]. Lastly, when compared to thrombin 
alone, FS appear to provide significantly more effective (and generally faster) 
 hemostasis [55].
5. Calcium alginate
The use of calcium alginate (CA) to help control hemorrhage and improve graft 
take has been described in burn surgery for quite some time [56]. In comparison 
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to epinephrine applications and fibrin-based products, CA is not as effective as 
a hemostatic agent [57]. However, as a donor site dressing CA has been observed 
to provide superior hemostasis for skin-graft harvesting sites when compared to 
plain sterile gauze or paraffin gauze dressings [58–60]. The alginate dressing also 
has several other potential advantages, including excellent absorptive properties, 
biodegradability, ease of postoperative maintenance/wound care, improved healing 
time, as well as notably lower risk of infection [61]. Still, CA donor site dressings 
are not without potential complications, including reported instances of dermal 
calcifications [62].
6. Platelet rich plasma
Investigational studies on the use of platelet-rich plasma (PRP) in burn surgery 
are scarce overall, with further paucity of data on PRP’s hemostatic properties 
[63, 64]. Nevertheless, there is growing evidence that supports the use of PRP as 
a promoter of wound bed hemostasis prior to split thickness skin graft (STSG) 
placement, with the intent of decreasing the rates of hematoma formation under 
a STSG [65, 66]. Although PRP may have additional benefits, including pain 
reduction, improved skin graft adherence, and decreased skin graft healing times 
[67, 68], these findings have not been consistent among all available clinical reports 
[69]. One case–control study comparing PRP extracted from burn patients to 
that from matched healthy volunteers demonstrated similar platelet counts and 
levels of growth factors [70]. It is important to mention that PRP (and its various 
subcomponents) may also play a role as a regenerative medicine approach due to 
its rich growth factor content and non-immunogenic properties [71]. For example, 
this may be important in promoting skin graft donor site healing. Finally, while 
the platelets in burn patients appear to have normal functionality, further studies 
focusing on determining the quantitative hemostatic ability of PRP in the setting of 
thermal injury are needed to fully understand its potential [72].
7. Tranexamic acid
Tranexamic acid (TXA) is an antifibrinolytic agent, whose use topically and 
intravenously has been shown to decrease traumatic and perioperative blood loss, 
reducing the need for blood transfusions in multiple surgical applications [73–76]. 
Despite the promising overall results from the trauma literature, there are very few 
studies evaluating TXA use in burn patients [77, 78]. Overall, available data show 
promise; however, there is also evidence of cytotoxicity in the context of wound 
re-epithelialization, especially with prolonged use/exposure [79]. One retrospective 
cohort study analyzing the effect of intraoperative intravenous TXA administra-
tion in major burn patients (>20% TBSA) undergoing primary wound excision and 
grafting found that intravenous TXA administration significantly decreased the 
amount of blood administered during and up to 24 hours after the index operation. 
The series of patients included in the study received a TXA infusion 15 minutes 
prior to surgical incision as a loading dose of 10 mg/kg given over 5 minutes, 
followed by continuous infusion of 1 mg/kg/h until the end of the procedure. 
Multivariate analysis revealed TXA to be protective against transfusion (Odds Ratio 
of 0.2) [77]. Secondary findings revealed no difference in mortality or thrombo-
embolic disease, and some improvement of graft survival in the TXA group [77]. A 
prospective randomized trial of single dose intravenous TXA (15 mg/kg diluted to 
25 ml with isotonic saline over 10 min) prior to wound excision in 50 adult patients 
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with >20% TBSA burns found that the patients who received TXA experienced, on 
average, about 400 mL less intraoperative blood loss and required significantly less 
colloid replacement in comparison to those who received an equal volume of only 
isotonic saline before induction of general anesthesia [78]. Further confirmatory 
prospective clinical trials will be helpful in clarifying intravenous TXA’s place in 
burn surgery blood management protocols. In terms of TXA use as a topical agent, 
one case report concluded that such application of TXA, in addition to standard 
methods, is a safe and effective way of controlling bleeding during burn surgery 
[80]. Future well-designed, adequately powered comparative studies analyzing 
blood loss, graft survival, epithelialization rate, and infections are warranted.
8. NuStat topical hemostat: clinical equivalency with lower cost
One prospective randomized control trial compared NuStat® (a product con-
taining patented Hemafiber Technology™ by Beeken Miomedical, Stoughton, MA) 
to the institutional standard of care for controlling bleeding at both burn and donor 
sites. Briefly, NuStat® is a two-component product consisting of continuous fila-
ment silica and bamboo cellulose, a combination that when used together promotes 
hemostasis by activating the clotting cascade. Though potentially underpowered, 
hemostasis provided by the NuStat® dressing was found to be at least comparable 
to other currently utilized approaches (epinephrine- and thrombin-soaked non-
adherent dressings, saline-soaked laparotomy sponges, and elastic bandage wraps) 
[81]. While the reported results show clinical equivalency of NuStat® compared 
to historic standard of care, the overall cost of wound care was significantly lower 
using the novel hemostatic dressing [81]. It is unlikely that these findings alone will 
change operative practices by most burn surgeons; however, the study does provide 
an important new treatment option in an area of clinical care that has seen little 
progress during the past few decades.
9. Recombinant tissue factor
As an initiator of the coagulation cascade, tissue factor is both an intriguing and 
a promising candidate for use as a topical hemostatic agent. Based on compelling 
preclinical and clinical data [82–84], a phase II randomized parallel double-blinded 
study was published in 2017 comparing an investigational topical hemostatic 
agent “TT-173” that is based on recombinant tissue factor (rTF) to a placebo, 
for establishing hemostasis at the donor site in burn surgery. The investigational 
agent “TT-173” reportedly decreased bleeding time from 7 minutes to 3 minutes 
without causing adverse events, systemic absorption, immunogenic reaction, or 
perturbance of donor site healing [85]. Further research into rTF as a potential new 
adjunct in operative hemostasis in burn surgery is clearly warranted based on the 
above reports.
10. Hydrogen peroxide
Hydrogen peroxide used as a 3% soak applied to the tangential excision site has 
been reported as a potentially effective and safe means of achieving hemostasis 
in a burn patient with platelet dysfunction. In one published experience, the 
investigators reported no apparent morbidity related to corrosive damage or lipid 
peroxidation, which is a known complication associated with higher concentrations 
Contemporary Applications of Biologic Hemostatic Agents across Surgical Specialties - Volume 1
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of hydrogen peroxide. With the hydrogen peroxide sufficiently irrigated from the 
wound bed prior to application of the STSG, the investigators saw excellent graft 
take [86]. Other reported uses of hydrogen peroxide as a topical hemostat, either 
alone or in combination with another agent, have been described in maxillofacial 
and otolaryngology applications [87, 88]. Benefits of the above approach included 
less blood loss, shorter procedure times, and fewer surgical ties used [87, 88].
11. Oxidized regenerated cellulose
There is some evidence to suggest that the application of oxidized regenerated 
cellulose (ORC) products to skin graft donor sites may significantly shorten wound 
healing and recovery time [89]. The difference between ORC-treated donor sites 
and fine mesh gauze treated with nitrofurazone (FMN) was substantial, with 
semiclosed ORC dressing group achieving healing endpoint in 6.5 days (compared 
to 9.9 days for FMN) and closed ORC dressing group achieving healing in 5.4 days 
(compared to 8.4 days for FMN) [89]. With limited literature on the use of ORC-
based products in burn surgery, further research is warranted to determine safety 
and efficacy of this topical hemostatic approach.
12.  Granular zeolite: a topical hemostatic material capable of causing 
burns
Although this chapter focuses on topical hemostats in burn surgery, one well-
known and highly effective topical hemostat warrants a special mention as a risk-
factor for thermal injury [90]. Granular zeolite (GZ, also known as QuikClot®) is 
a material derived from lava rocks and introduced for field use in the early 2000’s 
[91]. The material is effective via a complex mechanism that involves an exothermic 
reaction coupled with absorption of water and the ability to concentrate coagulation 
factors [91–93]. There are multiple reports of GZ causing both cutaneous and inter-
nal burns due to excessive heat generation [90, 94, 95]. In fact, the original formula-
tion was deemed sufficiently dangerous – able to reach temperatures up to 65°C 
(149°F) and cause burns to the operating surgeon – that it was discontinued in 2008 
and replaced with a modified QuikClot® ACS and kaolin-containing QuikClot 
Combat Gauze formulation [91]. Based on the above observations, GZ should not 
be utilized in burn surgery, at least in its currently available formulation(s).
13. Conclusions
Although their use is certainly not novel in burn surgery, the awareness of 
biosurgical hemostats appears to be far from adequate. Given the above, the goal 
of this chapter was to both review published applications of biosurgicals in burn 
surgery and to increase awareness of these potentially valuable adjuncts. Especially 
important in this context is the emergence of new research involving novel topical 
hemostatic agents, such as the Hemafiber Technology™ and recombinant tissue 
factor. Similar to other surgical specialties, the management of thermal injuries 
focuses increasingly on optimizing care protocols, maximizing outcomes, and mini-
mizing the need for potentially harmful and costly interventions such as blood and 
blood product transfusions. The authors believe that the current chapter provides a 
solid foundation of relevant clinical knowledge in the emerging area of biosurgical 
hemostasis in burn surgery.
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